Whalesbook
Star Health ka FY26 Performance: Growth toh dikhi!
Dekho, March 2026 ko khatam hone wale saal mein Star Health ne operational front par kaafi improve kiya hai. Premium growth aur loss ratio mein sudhar se yeh numbers aaye hain. Pehle toh stock ne bhi acha jump mara tha, Nifty 50 ke saath.
Kahan se aaya yeh growth aur profit?
Is quarter mein company ka Profit After Tax (PAT) 16% badh kar ₹911 Crore raha. Iska main reason hai Gross Written Premium (GWP) mein 16% ki tezi, jo ₹20,369 Crore tak pahunch gaya. Retail health premiums toh aur bhi bhage, 20% badh kar ₹19,341 Crore ho gaye, jisse company ka retail segment mein 31% market share maintain hai. Sabse important, combined ratio 98.8% par aa gaya, jo FY25 ke 101.1% se kaafi better hai. Q4 FY26 mein toh yeh 95.7% tha. Is sabse pehle toh stock 13.32% tak bhaga tha!
Sector kya bolta hai aur Star Health ka valuation?
Overall, Indian non-life insurance sector bhi FY26 mein 9% grow karke ₹3.36 lakh Crore tak pahunch gaya. Health insurance toh 15.6% grow kar raha hai, mostly retail policies ki wajah se. Star Health bhi is trend ko follow kar raha hai. Lekin stock ka valuation dekhne wala hai. Star Health ka P/E ratio lagbhag 38.4x hai, jo competitors jaise ICICI Lombard (31.88x se 37.75x) se zyada hai. SBI General Insurance toh aur bhi conservative hai. Pichhle records dekhe toh, jab bhi growth numbers acche aate hain, stock thodi der mein stable ho jata hai.
Valuation Concerns aur Target Reduction
Result toh acche hain, but valuation par sawal uth rahe hain. 38.4x ka P/E ratio competitors se upar hai. Company ka Return on Equity (ROE) bhi 6.70% se 9.67% ke beech raha hai, jo is valuation ko fully support karta nahi lagta. Aur ek bada update ye hai ki Star Health ne FY28 ka GWP target ₹30,000 Crore se kam karke ₹27,500 Crore kar diya hai. Lagta hai ab aggressive expansion se zyada profit par focus karenge. Management disciplined execution ki baat kar raha hai, but loss ratio maintain karna crucial hoga, especially jab competition aur price adjustments badh rahe hain. Pehle bhi aise positive results ke baad stock mein dip dekha gaya hai.
Analysts ka view aur company ki governance
Analysts generally positive hain, 22 analysts mein se 'Buy' rating de rahe hain, aur average target price ₹528.14 hai. Motilal Oswal ne bhi 'Buy' rating maintain rakhi hai, retail aur banca channel se growth expect kar rahe hain. Management sustainable growth, digital innovation par focus kar raha hai. Recent corporate updates mein Insider Trading Policy update aur promoter reclassification approval shamil hai. FY26 results bhi approve ho gaye hain, jisme koi issue nahi mila.